NVIDIA
NVDA
Tesla
TSLA
Palantir
PLTR
4
BigBear.ai Holdings
BBAI
5
Advanced Micro Devices
AMD
US Stock MarketDetailed Quotes
AXSM Axsome Therapeutics
- 127.540
- +1.130+0.89%
Close Feb 28 16:00 ET
- 127.540
- 0.0000.00%
Post 20:01 ET
6.22BMarket Cap-21.29P/E (TTM)
128.770High126.030Low851.34KVolume126.410Open126.410Pre Close108.41MTurnover2.32%Turnover RatioLossP/E (Static)48.77MShares139.13052wk High109.10P/B4.68BFloat Cap64.11052wk Low--Dividend TTM36.67MShs Float139.130Historical High--Div YieldTTM2.17%Amplitude1.940Historical Low127.342Avg Price1Lot Size
Axsome Therapeutics Stock Forum
Can This New Migraine Drug Replace CGRP Inhibitors? Trial Shows 48x Success Rate
Axsome Shatters Expectations: Record 89% Growth for Depression Drug Auvelity, Pipeline Milestones Accelerate
Axsome Wins Major Victory: 15+ Years Market Protection for AUVELITY Secured in Patent Deal
has options
nfa be careful
1️⃣ Standard Designation: Standard designation is the typical pathway for drug development, involving preclinical studies and three phases of clinical trials to assess safety and efficacy thoroughly.
2️⃣ Orphan Designation: Reserved for drugs targeting rare diseases, this designation offers incentives like tax credits and marketing exclusivity to encourage development for underserved ...
$BioCardia (BCDA.US)$ Phase 3
$Atea Pharmaceuticals (AVIR.US)$ Phase 3
$Crinetics (CRNX.US)$ Phase 3
$Axsome Therapeutics (AXSM.US)$ Phase 3
$ROCHE HOLDING AG (RHHBY.US)$ Phase 3
$ACADIA Pharmaceuticals (ACAD.US)$ Phase 3
$Sellas Life Sciences (SLS.US)$ Phase 3
$Aquestive Therapeutics (AQST.US)$ Phase 3
$Jaguar Health (JAGX.US)$ Phase 3
$Novocure (NVCR.US)$ Phase 3
$Johnson & Johnson (JNJ.US)$ Phase 3
• Ph 3 data (also Ph 2/3 in AD).
• Buntanetap for Parkinson’s Disease.
• Exp Jan '24 but delayed (est this qtr).
2. $Axsome Therapeutics (AXSM.US)$
• Ph 3 data (SYMPHONY).
• AXS-12 for Narcolepsy.
• AXS-12 has Orphan Drug Designation.
3. $G1 Therapeutics (GTHX.US)$
• Ph 3 Overall Survival (OS) data.
• Trilaciclib (combo) for breast cancer (mTNBC).
• DMC recommended continuation earlier in Feb.
4. $Crinetics (CRNX.US)$
• Ph 3 data (PATHFND...
$Pfizer (PFE.US)$ Phase 3
$Palatin Technologies (PTN.US)$ Phase 3
$Annovis Bio (ANVS.US)$ Phase 3
$BioCardia (BCDA.US)$ Phase 3
$Atea Pharmaceuticals (AVIR.US)$ Phase 3
$Ironwood Pharmaceuticals (IRWD.US)$ Phase 3
$Alnylam Pharmaceuticals (ALNY.US)$ Phase 3
$Axsome Therapeutics (AXSM.US)$ Phase 3
$ $Novocure (NVCR.US)$ Phase 3
$ROCHE HOLDING AG (RHHBY.US)$ Phase 3
$FibroGen (FGEN.US)$ Phase 3
$ACADIA Pharmaceuticals (ACAD.US)$ Phase 3
$Sellas Life Sciences (SLS.US)$...
No comment yet